Elucid

Bottom line

Elucid is FDA 510(k)-cleared software for quantitative coronary plaque analysis from CCTA scans, targeting cardiologists and radiologists who need granular plaque characterization beyond visual reads. The 2024 clearance positions it as a late entrant to a market already occupied by more established players like Cleerly and HeartFlow.

Pricing is enterprise-only with no published tiers, which signals IDN-scale deals rather than solo-practice accessibility. The tool fits large cardiology groups and health systems already performing high-volume CCTA who want to layer quantitative risk stratification on top of existing workflows.

The evidence base is concerningly thin. Zero clinician discussion in public forums, minimal peer-reviewed validation outside vendor-affiliated studies, and opacity around real-world deployment timelines all suggest this is a cautious early-adopter play, not a proven workhorse. CMIOs evaluating cardiovascular AI should benchmark Elucid against Cleerly's deeper validation track record before committing.

Why we picked it

Elucid earned FDA 510(k) clearance in 2024 for coronary plaque quantification, which establishes baseline regulatory credibility. The clearance pathway means the FDA found it substantially equivalent to predicate devices, a lower bar than de novo but still meaningful for hospital procurement committees evaluating liability and compliance.

The tool addresses a real clinical gap: CCTA visual reads are operator-dependent and miss subtle plaque features (low-attenuation plaque, pericoronary adipose tissue) that predict future events. Quantitative analysis software standardizes these measurements and surfaces biomarkers that correlate with plaque vulnerability, which aligns with cardiology's shift toward precision risk stratification.

However, this is not a silo pick. Cleerly has more published validation, broader EHR integration partnerships, and visible clinician adoption. Elucid's inclusion here reflects its regulatory status and category relevance, not superiority. It is a tool worth monitoring as it builds evidence, not one to deploy ahead of better-validated alternatives unless specific institutional needs (vendor lock-in avoidance, niche integration requirements) justify the trade-off.

What it does well

Elucid automates the extraction of plaque volume, composition (calcified, non-calcified, low-attenuation), and pericoronary fat measurements from standard CCTA scans. These outputs go beyond stenosis grading to characterize plaque vulnerability, which is clinically useful for shared decision-making around statin intensification, aspirin initiation, or invasive coronary angiography. The automation eliminates the inter-reader variability documented in manual plaque scoring.

The FDA clearance signals that Elucid met safety and effectiveness benchmarks for its intended use, which matters for hospital legal and compliance teams. A 510(k) clearance also facilitates billing and reimbursement discussions, though CPT code availability for AI-enhanced CCTA reads remains institution-specific and payer-dependent.

The vendor's focus on quantitative biomarkers positions Elucid as a research-friendly tool. Academic medical centers conducting coronary plaque trials or building cardiovascular risk registries may find value in the standardized output format, assuming Elucid supports data export in usable formats (DICOM structured reports, HL7 FHIR, or flat files for research databases).

Where it falls short

The evidence base is alarmingly sparse. A 2024 study in Current Problems in Cardiology evaluated intra- and inter-reader reproducibility of quantitative coronary plaque analysis on CCTA, demonstrating that automated tools can achieve consistent measurements. However, that study did not name Elucid specifically, and the vendor's own peer-reviewed validation portfolio is not publicly prominent. Zero mentions on Reddit's physician communities (r/medicine, r/Radiology, r/Cardiology) suggest negligible organic clinician adoption or discussion as of mid-2026.

Pricing opacity is a major friction point. Enterprise-only models with no published tiers mean lengthy procurement cycles, custom contracts, and unpredictable total cost of ownership. Solo cardiologists and small groups are effectively excluded. Even IDNs face negotiation asymmetry without public benchmarks to anchor pricing conversations.

EHR integration depth is unknown. The vendor's website does not specify which EHR platforms Elucid connects to, whether integration is read-only or bidirectional, or how results flow into clinical workflows (discrete fields in the EHR, PDF attachments, PACS-only reports). This ambiguity raises red flags for CMIOs who need guarantees that quantitative plaque data will surface at the point of care, not languish in siloed reporting systems.

The competitive landscape is crowded and Elucid is late. Cleerly has published extensively, partners with major health systems, and has visible presence at cardiology conferences. HeartFlow dominates the FFR-CT niche. Elucid's differentiation story is unclear from public materials, which leaves evaluators uncertain whether this tool offers unique value or is a me-too entrant chasing market share.

Deployment realities

CCTA plaque analysis software requires PACS integration, radiology IT collaboration, and cardiologist buy-in. Elucid likely ingests DICOM images from the PACS, processes them on vendor-hosted cloud infrastructure (or on-premises servers depending on contract terms), and returns structured reports. The exact workflow (manual upload vs automated routing) is not documented publicly, so expect discovery calls and technical scoping before deployment.

Training overhead for radiologists and cardiologists should be minimal if the tool produces intuitive visual reports (color-coded plaque maps, quantitative tables). However, clinician skepticism of AI-generated risk scores is real. Education on how to interpret low-attenuation plaque percentages, pericoronary fat attenuation, and other novel biomarkers will require dedicated onboarding sessions, ideally led by a cardiologist champion who understands the evidence base and can contextualize the outputs.

Change management is the hidden cost. Radiologists accustomed to visual CCTA reads may resist adding quantitative software to their workflow, especially if it increases report turnaround time or creates ambiguous findings that require cardiology follow-up. Hospital cardiovascular service lines need alignment across radiology, cardiology, and IT before deployment, or the tool will sit unused despite the contract spend.

Pricing realities

Elucid's enterprise-only pricing model means no transparent tiers. Expect per-scan fees, annual subscription minimums, or volume-based tiers negotiated case-by-case. Industry norms for CCTA AI tools range from $50 to $200 per scan, but without public benchmarks for Elucid, buyers lack leverage. Hidden costs likely include implementation fees (PACS integration, IT setup), support contracts, and ongoing software updates.

ROI math is speculative. If quantitative plaque analysis prevents one unnecessary catheterization per 50 scans (by reclassifying intermediate-risk lesions as low-risk based on plaque composition), the cost avoidance could justify the software spend. However, that assumes cardiologists trust the AI outputs enough to alter clinical decisions, which requires validation studies showing non-inferiority or superiority to standard-of-care visual reads plus clinical judgment.

Contract lock-in is probable. Enterprise SaaS agreements in healthcare typically run 12 to 36 months with auto-renewal clauses and punitive early-termination fees. Buyers should negotiate pilot periods, performance guarantees (e.g., 95% uptime, sub-24-hour report turnaround), and exit ramps if adoption fails to materialize.

Compliance + integration depth

Elucid holds FDA 510(k) clearance, which satisfies the regulatory floor for clinical use in the United States. HIPAA compliance is table stakes for any cloud-based medical imaging tool; expect BAAs (business associate agreements) as part of the contract. SOC 2 Type II and HITRUST certifications are not listed in public materials, which is a yellow flag for enterprise buyers who require third-party security audits before onboarding new vendors.

EHR integration specifics are absent from public documentation. Buyers need to confirm which EHR platforms Elucid supports (Epic, Cerner Oracle Health, Meditech, Allscripts), whether integration is unidirectional (results pushed to EHR as attachments) or bidirectional (discrete data fields updated), and how results appear in cardiologist workflows (embedded in the chart, separate viewer, PACS-only). Without named EHR partnerships, assume custom HL7 or FHIR interface work will be required, adding months to deployment timelines.

Specialty-society endorsements are not evident. The American College of Cardiology and Society of Cardiovascular Computed Tomography have published appropriate-use criteria for advanced CCTA analysis, but Elucid is not prominently featured in society guidelines or educational materials as of mid-2026, which limits its credibility among evidence-driven cardiologists.

Vendor stability + roadmap

Elucid Bioimaging is a private company with limited public disclosure of funding rounds, leadership, or customer references. The absence of press releases announcing health system partnerships or conference presentations at major cardiology meetings (ACC, AHA, SCCT) suggests the vendor is either early-stage or deliberately low-profile. Buyers should request customer references and ask pointed questions about runway, leadership tenure, and post-sales support capacity.

The 2024 FDA clearance indicates recent commercialization, which means the product is likely still iterating based on early-adopter feedback. Roadmap visibility is poor; the vendor's website does not outline planned features, additional FDA clearances (e.g., expanded indications), or integration partnerships. This opacity is acceptable for a startup but risky for IDNs making multi-year commitments.

Acquisition risk is non-zero. Cardiovascular AI is a hot M&A category, with larger players (Siemens Healthineers, GE Healthcare, Philips) acquiring point-solution vendors to build comprehensive imaging portfolios. If Elucid is acquired, expect product integration into the acquirer's ecosystem, which could improve EHR connectivity but also force platform migrations or pricing changes.

How it compares

Cleerly is the dominant CCTA plaque analysis platform as of 2026, with extensive peer-reviewed validation, partnerships with Epic and major IDNs, and visible adoption among academic medical centers. Cleerly wins on evidence base, EHR integration maturity, and brand recognition. Choose Cleerly if you need a proven tool with established workflows and reimbursement pathways.

HeartFlow focuses on FFR-CT (fractional flow reserve derived from CT) rather than plaque composition, addressing a different clinical question (ischemia assessment vs plaque vulnerability). HeartFlow has CPT Category I codes and robust reimbursement, making it easier to operationalize. Choose HeartFlow if functional ischemia assessment is the priority; choose Elucid if plaque characterization for risk stratification is the goal.

Ischemia AI tools from radiology AI vendors (Aidoc, Riverain, others) increasingly offer coronary calcium scoring and basic plaque detection as part of broader cardiovascular bundles. These tools are less specialized than Elucid but may already be embedded in your PACS workflow via existing contracts. Choose bundled tools if incremental cost is near zero and quantitative precision is not mission-critical.

Elucid's niche, if it exists, would be institutions seeking vendor diversity to avoid Cleerly lock-in, or those with specific research needs that align with Elucid's quantitative output format. However, without public differentiation, Elucid feels like a second-choice option rather than a category leader.

What clinicians say

Zero mentions of Elucid were found in Reddit physician communities (r/medicine, r/Cardiology, r/Radiology) as of mid-2026. This absence is striking given that competing tools like Cleerly and HeartFlow generate regular discussion around reimbursement, workflow integration, and clinical utility. The silence suggests negligible organic adoption or that early users are not engaged in online professional communities.

The lack of clinician discourse is a red flag for buyers. Tools that solve real workflow pain points generate word-of-mouth visibility, vendor-agnostic reviews, and crowdsourced implementation tips. Elucid's invisibility could mean it is too new to have built a user base, or that early adopters have not found it differentiated enough to warrant discussion. Either way, buyers should seek direct customer references from the vendor and speak to cardiologists and radiologists at peer institutions before committing.

What the literature says

Peer-reviewed validation of Elucid specifically is thin. A 2024 study in Current Problems in Cardiology evaluated intra- and inter-reader reproducibility of quantitative coronary plaque analysis on CCTA, demonstrating that automated tools can achieve high consistency across readers. While this study did not name Elucid, it supports the broader premise that AI-driven plaque quantification reduces variability compared to manual reads.

A 2023 study in Frontiers in Cardiovascular Medicine analyzed quantitative imaging biomarkers from the EVAPORATE trial, which used coronary CTA to assess plaque characteristics. The study found that low-attenuation plaque and pericoronary adipose tissue are meaningful predictors of cardiovascular events, validating the biomarkers that tools like Elucid aim to measure. However, this evidence supports the category, not Elucid's specific algorithm or clinical performance.

The absence of Elucid-specific randomized controlled trials, real-world evidence studies, or head-to-head comparisons with Cleerly is a major evidence gap. Buyers evaluating this tool should demand vendor-provided validation data, ideally published in peer-reviewed cardiology or radiology journals, before assuming clinical equivalence to better-studied competitors. Until that evidence emerges, Elucid remains an unproven option in a category where validation rigor directly impacts adoption confidence.

Who it's for

Elucid is potentially suitable for large cardiology groups and IDN cardiovascular service lines performing high-volume CCTA (500+ scans annually) who want quantitative plaque analysis to inform risk stratification and treatment decisions. These organizations need established PACS infrastructure, IT resources for integration, and cardiologist champions willing to interpret novel biomarkers. The enterprise pricing model excludes solo practitioners and small groups.

Academic medical centers conducting cardiovascular imaging research may find value in Elucid if the tool supports flexible data export for registry studies or clinical trials. However, this assumes Elucid's outputs are research-grade and that the vendor supports academic pricing or collaboration agreements, neither of which is confirmed in public materials.

Elucid is not for: solo cardiologists (no accessible pricing tier), community hospitals with low CCTA volume (ROI is dubious below 300 scans per year), or risk-averse health systems that require deep peer-reviewed validation before adopting AI (the evidence base is too thin). Institutions already using Cleerly should not switch to Elucid without compelling differentiation, which is not evident from public information. CMIOs evaluating cardiovascular AI for the first time should prioritize Cleerly or HeartFlow over Elucid based on maturity, evidence, and EHR integration track record.

The verdict

Elucid is FDA-cleared and addresses a legitimate clinical need, but the evidence base is too thin to recommend it ahead of Cleerly for most buyers. The absence of clinician discussion, sparse peer-reviewed validation, and opaque EHR integration all signal an immature product that requires early-adopter tolerance for unknowns. If you are evaluating CCTA plaque analysis software for the first time in 2026, choose Cleerly for its deeper validation and proven integration pathways. If you already use Cleerly and are exploring alternatives to diversify vendors, Elucid merits a pilot, but only after direct customer references and a proof-of-concept deployment confirm it meets your workflow and accuracy requirements.

For IDNs with unique requirements (specific PACS integration needs, research collaborations, vendor negotiation leverage over Cleerly), Elucid could be worth a structured evaluation: demand peer-reviewed validation data, negotiate a 90-day pilot with exit clauses, and involve both radiologists and cardiologists in workflow testing before signing a multi-year contract. Do not assume FDA clearance equals clinical validation or operational readiness.

The broader lesson: cardiovascular AI is moving fast, but regulatory clearance is a floor, not a ceiling. Tools need published evidence, clinician adoption, and transparent integration to earn trust. Elucid has the clearance but lacks the rest. Monitor it as the vendor builds evidence, but deploy proven alternatives unless your institution has specific reasons to bet on an unproven entrant.